These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 28199067)
41. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Tacha D; Zhou D; Cheng L Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):293-9. PubMed ID: 21285870 [TBL] [Abstract][Full Text] [Related]
42. Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens. Zhao L; Guo M; Sneige N; Gong Y Am J Clin Pathol; 2012 Feb; 137(2):304-9. PubMed ID: 22261458 [TBL] [Abstract][Full Text] [Related]
43. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939 [TBL] [Abstract][Full Text] [Related]
44. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma]. Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635 [TBL] [Abstract][Full Text] [Related]
45. HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect. Liu D; Kong D; Li J; Gao L; Wu D; Liu Y; Yang W; Zhang L; Zhu J; Jin X J Ovarian Res; 2018 Jun; 11(1):47. PubMed ID: 29903044 [TBL] [Abstract][Full Text] [Related]
46. PAX2 and PAX8: useful markers for metastatic effusions. Waters L; Crumley S; Truong L; Mody D; Coffey D Acta Cytol; 2014; 58(1):60-6. PubMed ID: 24334997 [TBL] [Abstract][Full Text] [Related]
47. Serum human epididymis protein 4 (HE4) may be a better tumor marker in early lung cancer. Zeng Q; Liu M; Zhou N; Liu L; Song X Clin Chim Acta; 2016 Apr; 455():102-6. PubMed ID: 26851650 [TBL] [Abstract][Full Text] [Related]
48. [HE4 and CA125 in ovarian cancer]. Manolov V; Marinov B; Vasilev V Akush Ginekol (Sofiia); 2012; 51(2):21-8. PubMed ID: 23234010 [TBL] [Abstract][Full Text] [Related]
49. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward? Azzam AZ; Hashad DI; Kamel NA Arch Gynecol Obstet; 2013 Jul; 288(1):167-72. PubMed ID: 23361457 [TBL] [Abstract][Full Text] [Related]
50. CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2. Altree-Tacha D; Tyrrell J; Haas T Arch Pathol Lab Med; 2017 Jan; 141(1):144-150. PubMed ID: 28029907 [TBL] [Abstract][Full Text] [Related]
51. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors. Long KB; Srivastava A; Hirsch MS; Hornick JL Am J Surg Pathol; 2010 May; 34(5):723-9. PubMed ID: 20414099 [TBL] [Abstract][Full Text] [Related]
52. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study. El Hag MI; Ha J; Farag R; El Hag AM; Michael CW Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760 [TBL] [Abstract][Full Text] [Related]
53. Gynecologic Serous Carcinoma: An Immunohistochemical Analysis of Malignant Body Fluid Specimens. Ren S; Klump W Arch Pathol Lab Med; 2019 Jun; 143(6):677-682. PubMed ID: 29688031 [TBL] [Abstract][Full Text] [Related]
54. PAX8 expression in cancerous and non-neoplastic tissue: a tissue microarray study on more than 17,000 tumors from 149 different tumor entities. Gorbokon N; Baltruschat S; Lennartz M; Luebke AM; Höflmayer D; Kluth M; Hube-Magg C; Hinsch A; Fraune C; Lebok P; Bernreuther C; Sauter G; Marx AH; Simon R; Krech T; Clauditz TS; Jacobsen F; Burandt E; Steurer S; Minner S Virchows Arch; 2024 Sep; 485(3):491-507. PubMed ID: 39105782 [TBL] [Abstract][Full Text] [Related]
55. Human epididymis protein 4 (HE4) is a novel immunohistochemical marker of neuroendocrine differentiation. Su W; Yang K; Jiang H; Song H; Feng K; Li Q Virchows Arch; 2022 Sep; 481(3):433-441. PubMed ID: 35913578 [TBL] [Abstract][Full Text] [Related]
56. HE4 tissue expression and serum HE4 levels in healthy individuals and patients with benign or malignant tumors: a systematic review. Karlsen NS; Karlsen MA; Høgdall CK; Høgdall EV Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2285-95. PubMed ID: 25169975 [TBL] [Abstract][Full Text] [Related]
57. Targeting and neutralizing human epididymis protein 4 by novel nanobodies to suppress ovarian cancer cells and attenuate cisplatin resistance. Yu J; Guo Y; Gu Y; Li F; Song H; Nian R; Fan X; Liu W Int J Biol Macromol; 2022 Feb; 199():298-306. PubMed ID: 35016970 [TBL] [Abstract][Full Text] [Related]
58. [Correlation between eIF3a and HE4 expression and ovarian cancer]. Wang J; Luo C; Wang Y; Tang Y; Fang K; Zeng L; Zhang Y Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Dec; 39(12):1240-5. PubMed ID: 25544161 [TBL] [Abstract][Full Text] [Related]
59. Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma. Sethi A; Kumar L; Mathur S; Mahey R; Kachhawa G; Bhatla N South Asian J Cancer; 2022 Apr; 11(2):125-132. PubMed ID: 36466984 [TBL] [Abstract][Full Text] [Related]
60. Claudin-18 as a Marker for Identifying the Stomach and Pancreatobiliary Tract as the Primary Sites of Metastatic Adenocarcinoma. Li WT; Jeng YM; Yang CY Am J Surg Pathol; 2020 Dec; 44(12):1643-1648. PubMed ID: 32925194 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]